Package 0615-8140-39

{"route": ["ORAL"], "spl_id": "8346efad-e6ee-4384-b042-95683f943e8e", "openfda": {"nui": ["N0000008486", "N0000185506", "N0000182140"], "unii": ["0H73WJJ391"], "rxcui": ["151226", "199888", "199889"], "spl_set_id": ["b0036d28-ca99-42c6-81ad-3c93f4a844a1"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "manufacturer_name": ["NCS HealthCare of KY, LLC dba Vangard Labs"]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8140-39)", "package_ndc": "0615-8140-39", "marketing_end_date": "20260731", "marketing_start_date": "20181220"}], "brand_name": "Topiramate", "product_id": "0615-8140_8346efad-e6ee-4384-b042-95683f943e8e", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 3A4 Inducers [MoA]", "Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "product_ndc": "0615-8140", "generic_name": "Topiramate", "labeler_name": "NCS HealthCare of KY, LLC dba Vangard Labs", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Topiramate", "active_ingredients": [{"name": "TOPIRAMATE", "strength": "100 mg/1"}], "application_number": "ANDA077627", "marketing_category": "ANDA", "marketing_end_date": "20260731", "marketing_start_date": "20090327"}